Node1	Edge_Type	Node2	Weight	Score	Paper_List	Original_Text
autistic	disease_to_mechanism	oxytocin	2	2.0	31096266|26336909	PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
autism	disease_to_mechanism	the serotonin transporter gene gene	1	2.274	15882779	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.
autism	disease_to_mechanism	the serotonin transporter gene loci	1	2.274	15882779	PMID:15882779; Original text:Our findings suggest that it is unlikely that DNA variations in the The serotonin transporter gene gene play a significant role in the genetic predisposition to autism in the Chinese Han population or that allelic heterogeneity at the The serotonin transporter gene loci dilutes potential disease-allele association.
schizophrenia	disease_to_mechanism	tcf4 gene	1	1.0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
schizophrenia	disease_to_mechanism	tcf4 gene product	1	1.0	23640545	PMID:23640545; Original text:The TCF4 gene is also a risk factor with highly significant linkage to schizophrenia, presumably via overexpression of the TCF4 gene product in the central nervous system.
autism spectrum disorder	disease_to_mechanism	gluten	1	3.775	26418822	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.
autism spectrum disorder	disease_to_mechanism	casein	1	3.775	26418822	PMID:26418822; Original text:When asked about the effects of the gluten-free and casein-free diet, 20-29% of the parents reported significant improvements on the autism spectrum disorder core dimensions.
autism	disease_to_mechanism	httlpr	1	12.384	16103890	PMID:16103890; Original text:Allele transmissions to individuals diagnosed with autism were biased only for HTTLPR, both for the narrow diagnosis of autism (P=0.035) and for the broader diagnosis of autism spectrum (P=0.007).
necrosis	disease_to_mechanism	tumor necrosis factor-α	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	interleukin-6	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	interferon-γ	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	il-6	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	ifn-γ	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
necrosis	disease_to_mechanism	tnf-α	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	tumor necrosis factor-α	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	interleukin-6	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	interferon-γ	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	il-6	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	ifn-γ	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
autistic	disease_to_mechanism	tnf-α	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	tumor necrosis factor-α	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	interleukin-6	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	interferon-γ	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	il-6	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	ifn-γ	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tumor	disease_to_mechanism	tnf-α	1	3.758	25729218	PMID:25729218; Original text:A number of studies have shown that the cytokine levels in the blood, brain, and cerebrospinal fluid (cerebrospinal fluid) of autistic subjects differ from that of healthy individuals; for example, a series of studies suggests that interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) are significantly elevated in different tissues in autistic subjects.
tuberous sclerosis	disease_to_mechanism	mtor	1	0.717	32222129	PMID:32222129; Original text:Animal studies have demonstrated the benefit of using mTOR inhibitors for various symptoms of Tuberous sclerosis complex, and they have been successfully translated into clinical trials with significant improvement in symptom burden.
autistic	disease_to_mechanism	growth hormone	1	2.118	10808042	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.
social behavior deficits	disease_to_mechanism	oxytocin	1	1.0	28864977	PMID:28864977; Original text:In the last decade, there has been a significant interest in using oxytocin to treat social behavior deficits in disorder.
autism	disease_to_mechanism	casein	1	4.546	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
spectrum disorder	disease_to_mechanism	casein	1	4.546	33573238	PMID:33573238; Original text:There has been a growing interest in the gastrointestinal system and its significance for autism spectrum disorder (spectrum disorder), including the significance of adopting a gluten-free and casein-free (GFCF) diet.
asd	disease_to_mechanism	neurotensin	3	12.175	23570274|23688533|25941080	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).|PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.|PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
asd	disease_to_mechanism	methylene tetrahydrofolate reductase	1	4.366	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
asd	disease_to_mechanism	mthfr	1	4.366	34440744	PMID:34440744; Original text:Furthermore, methylene tetrahydrofolate reductase (MTHFR) polymorphisms showed a significant influence on ASD risk.
autism	disease_to_mechanism	secretin	2	7.936	11699803|15590241	PMID:11699803; Original text:For the primary efficacy analysis, change of the Autism Diagnostic Observation Schedule social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73).|PMID:15590241; Original text:Journal of the Association of the Academy of Minority Physicians, 9, 9-15] reported an uncontrolled trial of secretin with three participants with autism, which apparently resulted in significant behavioral improvement.
autism	disease_to_mechanism	oxytocin	4	18.417	32398642|26336909|28534875|8759044	"PMID:32398642; Original text:Results showed that the time spent viewing both dynamic and static social vs. non-social stimuli was negatively associated with trait autism and significantly increased following intranasal oxytocin.|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:28534875; Original text:To our knowledge, this is the first trial to assess the dose-dependent effects of a single oxytocin administration in autism, with results indicating that a low dose of oxytocin can significantly modulate overt emotion salience despite minimal systemic exposure.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
williams syndrome	disease_to_mechanism	gtf2ird1	1	1.995	30008175	PMID:30008175; Original text:However, we report on two nominally significant SNPs in two genes that have been implicated in the cognitive and social phenotypes of Williams syndrome, BAZ1B and GTF2IRD1.
williams syndrome	disease_to_mechanism	baz1b	1	1.995	30008175	PMID:30008175; Original text:However, we report on two nominally significant SNPs in two genes that have been implicated in the cognitive and social phenotypes of Williams syndrome, BAZ1B and GTF2IRD1.
autism	disease_to_mechanism	beta-casomorphin	1	1.0	31813108	PMID:31813108; Original text:A 6-month GFCF diet do not induce significant changes in behavioral symptoms of autism and urinary beta-casomorphin concentrations.
autism	disease_to_mechanism	fra(x)	1	1.0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
autism	disease_to_mechanism	fra(x) males	1	1.0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
autistic	disease_to_mechanism	fra(x)	1	1.0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
autistic	disease_to_mechanism	fra(x) males	1	1.0	3513570	PMID:3513570; Original text:With an overall 7.7% frequency of fra(X) among autistic males and an estimated 12.3% of autism among fra(X) males, we conclude there is likely to be a significant association of fra(X) with autism.
asd	disease_to_mechanism	catechol-o-methyl transferase rs4680	1	1.0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
autism spectrum disorders	disease_to_mechanism	prolactin	1	1.0	15132762	PMID:15132762; Original text:Additionally subjects with autism spectrum disorders showed a significantly increased prolactin response to m-CPP compared to normal controls, with neither group responding to placebo.
decrease of developmental growth	disease_to_mechanism	insulin	1	1.0	27577546	PMID:27577546; Original text:We found a stronger effect of intranasal insulin, being significant for cognition and social skills, for children older than 3 years, who usually show a decrease of developmental growth.
autism spectrum disorders	disease_to_mechanism	oxytocin	1	1.0	12496956	PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.
repetitive behaviors	disease_to_mechanism	oxytocin	1	1.0	12496956	PMID:12496956; Original text:Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.
hyperactivity	disease_to_mechanism	mdr1	1	2.195	20166790	PMID:20166790; Original text:Subjects with either C/T or C/C (n = 16) genotypes showed a three-fold greater improvement than T/T MDR1 C3435T genotype (n = 6) (mean decrease of 15.1 +/- 12.6, or 50.7% from baseline, versus 4.5 +/- 5.1, or 15.6% from baseline) in parent-rated ABC Hyperactivity scores over 8 weeks (p = 0.03).
fragile x syndrome	disease_to_mechanism	fmr1 gene	1	5.359	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ataxia syndrome	disease_to_mechanism	fmr1 gene	1	5.359	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
ovarian insufficiency	disease_to_mechanism	fmr1 gene	1	5.359	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
tremor	disease_to_mechanism	fmr1 gene	1	5.359	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
fragile x	disease_to_mechanism	fmr1 gene	1	5.359	23129072	PMID:23129072; Original text:The expanded CGG mutation in the FMR1 gene, once thought to have clinical significance limited to fragile X syndrome, is now well established as the cause for other fragile X-associated disorders including fragile X-associated primary ovarian insufficiency and fragile X-associated tremor ataxia syndrome in individuals with the premutation (the premutation).
autism spectrum disorders	disease_to_mechanism	serotonin reuptake	1	1.0	27667009	PMID:27667009; Original text:The meta-analysis of case-control studies demonstrated a significantly increased risk of autism spectrum disorders in the children whose mothers were prenatally exposed to prenatal selective serotonin reuptake inhibitors during different exposure time windows (except third trimester).
autism spectrum disorders	disease_to_mechanism	serotonin	1	1.0	27667009	PMID:27667009; Original text:The significant association between preconception-only prenatal selective serotonin reuptake inhibitor exposure and autism spectrum disorders in the children and negative/inconsistent findings among cohort studies weaken the significant associations detected in this meta-analysis.
neuroinflammation	disease_to_mechanism	activator protein 1	1	1.0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_mechanism	nuclear factor kappa b	1	1.0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_mechanism	ap-1	1	1.0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
neuroinflammation	disease_to_mechanism	nf-κb	1	1.0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
autistic traits	disease_to_mechanism	casein-	1	1.0	15106205	PMID:15106205; Original text:However, the fourth outcome, reduction in autistic traits, reported a significant beneficial treatment effect for the combined gluten- and casein- free diet.
autistic traits	disease_to_mechanism	gluten-	1	1.0	15106205	PMID:15106205; Original text:However, the fourth outcome, reduction in autistic traits, reported a significant beneficial treatment effect for the combined gluten- and casein- free diet.
autistic	disease_to_mechanism	methionine synthase	1	1.0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
autism	disease_to_mechanism	the serotonin transporter gene polymorphisms	1	1.0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
autism	disease_to_mechanism	the	1	1.0	18286633	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.
asd	disease_to_mechanism	gws loci	1	5.869	28540026	PMID:28540026; Original text:Previous ASD the past decade genome-wide association studies have identified genome-wide significant (GWS) risk loci; however, these studies were of only of low statistical power to identify GWS loci at the lower effect sizes (odds ratio (odds ratio) <1.15).
asd	disease_to_mechanism	gws	1	5.869	28540026	PMID:28540026; Original text:Previous ASD the past decade genome-wide association studies have identified genome-wide significant (GWS) risk loci; however, these studies were of only of low statistical power to identify GWS loci at the lower effect sizes (odds ratio (odds ratio) <1.15).
anxiety	disease_to_mechanism	kappa-opioid receptor	1	1.0	32705569	PMID:32705569; Original text:The anxiety study showed that blocking the kappa-opioid receptor significantly affects functional magnetic resonance imaging ventral striatal activation in the monetary incentive delay task in anticipation of gain.
autism spectrum disorders	disease_to_mechanism	blood	1	1.0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
autism spectrum disorders	disease_to_mechanism	brain	1	1.0	28138831	PMID:28138831; Original text:A meta-analysis of blood Brain-derived neurotrophic factor in 887 patients with autism spectrum disorders and 901 control subjects demonstrated significantly higher Brain-derived neurotrophic factor levels in autism spectrum disorders compared to controls with the SMD of 0.47 (95% CI 0.07-0.86, p = 0.02).
alzheimer	disease_to_mechanism	nap	1	4.699	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
's disease	disease_to_mechanism	nap	1	4.699	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
cognitive impairment	disease_to_mechanism	nap	1	4.699	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
schizophrenia	disease_to_mechanism	nap	1	4.699	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
snippet	disease_to_mechanism	nap	1	4.699	27870441	PMID:27870441; Original text:NAP (NAP), an activity-dependent neuroprotective protein snippet drug candidate, protects cognition in patients suffering from amnestic mild cognitive impairment preceding Alzheimer's disease and significantly enhances functional daily activities in schizophrenia patients toward future development.
autistic	disease_to_mechanism	beta-endorphin	1	2.89	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
autistic	disease_to_mechanism	[3h]-par	1	4.34	11071017	PMID:11071017; Original text:The results showed a significantly higher density of [3H]-Par binding sites in autistic children than in healthy control subjects.
asd	disease_to_mechanism	interleukin-8	1	12.384	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interleukin)-1beta	1	12.384	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	transforming growth factor-β1	1	12.384	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	monocyte chemotactic protein-1	1	12.384	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interleukin-6	1	12.384	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interleukin	1	12.384	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
asd	disease_to_mechanism	interferon-gamma	1	12.384	24934179	PMID:24934179; Original text:Concentrations of interleukin (interleukin)-1beta (P<0.001), interleukin-6 (P=0.03), interleukin-8 (P=0.04), interferon-gamma (P=0.02), eotaxin (P=0.01) and monocyte chemotactic protein-1 (P<0.05) were significantly higher in the participants with ASD compared with the HC group, while concentrations of transforming growth factor-β1 were significantly lower (P<0.001).
anorexia nervosa	disease_to_mechanism	serum peripheral oxytocin	1	2.118	27183106	PMID:27183106; Original text:None of them (except serum peripheral oxytocin in anorexia nervosa) revealed significant differences.
autism	disease_to_mechanism	epidermal growth factor	1	2.195	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
autism	disease_to_mechanism	il-13	1	2.195	22070180	PMID:22070180; Original text:Serum levels of epidermal growth factor were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 pg/mL, n=19; p=0.0003).
autistic disorders	disease_to_mechanism	growth hormone	1	1.0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
repetitive behaviors	disease_to_mechanism	growth hormone	1	1.0	10649829	PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
autism spectrum disorders	disease_to_mechanism	pten	1	4.326	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
autistic	disease_to_mechanism	serotonin	1	1.0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
autistic	disease_to_mechanism	serotonin receptors	1	1.0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
antidepressants	disease_to_mechanism	slc6a4 5-httlpr polymorphism	1	1.0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
antidepressants	disease_to_mechanism	drd3 ser9gly	1	1.0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
diarrhea	disease_to_mechanism	secretin	1	5.359	11331721	PMID:11331721; Original text:Subgroupings based on cognitive level, the presence or absence of diarrhea, or a history of regression failed to show any significant therapeutic effects of secretin.
autism spectrum disorders	disease_to_mechanism	peripheral c-reactive protein	1	1.0	32272227	PMID:32272227; Original text:There was also a significant association between peripheral C-reactive protein concentration and Autism Spectrum Disorders after removing the studies identified by Galbraith plots.
autistic	disease_to_mechanism	peripheral c-reactive protein	1	1.0	32272227	PMID:32272227; Original text:In our study, peripheral C-reactive protein levels were significantly elevated in autistic children compared with healthy children.
autism	disease_to_mechanism	nmda receptor gene family	1	2.276	24605324	PMID:24605324; Original text:Gene expression patterns in the low-line animals show significant enrichment in autism-associated genes and the NMDA receptor gene family was identified among these.
social impairments	disease_to_mechanism	oxytocin	1	1.0	27651096	PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.
autistic	disease_to_mechanism	hemoglobin	2	2.0	25817280|25817280	PMID:25817280; Original text:The increments in the concentration of oxygenated hemoglobin in the pars opercularis of the inferior frontal gyrus in autistic subjects were significantly lower than those in the controls.|PMID:25817280; Original text:However, the concentrations of oxygenated hemoglobin in this area were significantly elevated in autistic subjects after they were trained to imitate emotional facial expressions.
metabolic abnormalities	disease_to_mechanism	low-density lipoprotein cholesterol	1	1.0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
metabolic abnormalities	disease_to_mechanism	high-density lipoprotein cholesterol	1	1.0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
autism	disease_to_mechanism	corticotropin-releasing factor	1	3.263	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
autism	disease_to_mechanism	neurotensin	1	3.263	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
asd	disease_to_mechanism	corticotropin-releasing factor	1	3.263	25941080	PMID:25941080; Original text:Corticotropin-releasing factor and neurotensin are significantly increased in serum of ASD children compared to normotypic controls further strengthening their role in the pathogenesis of autism.
psychiatric	disease_to_mechanism	oxytocin	1	2.118	26094200	"PMID:26094200; Original text:

It was brought to the authors' attention that there were several significant data analytic errors linked to the data entry and the software program that was used in the published meta-analysis comparing the effect of intranasal oxytocin versus placebo administration on psychiatric symptoms."
behavioral impairments	disease_to_mechanism	oxytocin	1	6.857	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neuronal	disease_to_mechanism	oxytocin	1	6.857	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
neurofunctional impairments	disease_to_mechanism	oxytocin	1	6.857	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
asociality	disease_to_mechanism	oxytocin	1	6.857	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
extended selective attention	disease_to_mechanism	oxytocin	1	6.857	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
dravet syndrome	disease_to_mechanism	foxg1	1	2.74	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
hunter syndrome	disease_to_mechanism	foxg1	1	2.74	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
motor delays	disease_to_mechanism	foxg1	1	2.74	28036350	PMID:28036350; Original text:Introduction of the 2.8MM probe-chromosomal microarray test led to significant improvements in condition-specific interventions including an 8.3% (p = 0.04) improvement in evaluation and therapy for gross motor delays caused by Hunter syndrome, a 27.5% (p = 0.03) increase in early cognitive intervention for FOXG1-related disorder, and an 18.2% (p<0.001) improvement in referrals to child neurology for Dravet syndrome.
fear	disease_to_mechanism	oxytocin	1	8.33	28467893	PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.
asd	disease_to_mechanism	cntnap2 gene	1	1.0	26559825	PMID:26559825; Original text:Overall, including case-control, sibs, and meta-analysis, we could not detect any significant association with the CNTNAP2 gene and high functioning ASD.
neurodevelopmental disorders	disease_to_mechanism	cntnap2	1	1.0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
asd	disease_to_mechanism	cntnap2	1	1.0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
intellectual delays	disease_to_mechanism	cntnap2	1	1.0	26559825	PMID:26559825; Original text:Our results point in the direction that CNTNAP2 may not play a major role in high functioning ASD, but rather seems to have a significance in neurodevelopmental disorders or in individuals displaying intellectual delays.
autism	disease_to_mechanism	dgcr6 genes	1	1.0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
autism	disease_to_mechanism	prodh	1	1.0	19736351	PMID:19736351; Original text:Individual significance (P = .02 without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
autism spectrum disorder	disease_to_mechanism	blood	1	3.998	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	vascular endothelial growth factor	1	3.998	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	vegf	1	3.998	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	blood neurotrophin-3	1	3.998	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	brain-derived neurotrophic factor	1	3.998	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
autism spectrum disorder	disease_to_mechanism	nerve growth factor	1	3.998	33420109	PMID:33420109; Original text:The results of random effect meta-analysis showed that the peripheral blood levels of brain-derived neurotrophic factor (Hedges' g = 0.302; 95% CI = 0.014 to 0.591; P = 0.040) , nerve growth factor (Hedges' g = 0.395; 95% CI = 0.104 to 0.686; P = 0.008) and vascular endothelial growth factor (VEGF) (Hedges' g = 0.097; 95% CI = 0.018 to 0.175; P = 0.016) in children with Autism Spectrum Disorder were significantly higher than that of healthy controls, whereas blood neurotrophin-3 (Hedges' g =
schaaf-yang syndrome	disease_to_mechanism	magel2	1	1.552	32702813	PMID:32702813; Original text:We highly suggest that the MAGEL2 gene should be added to gene-panels or gene-filters in next-generation sequencing-based diagnostics, which is of great significance for early diagnosis and early intervention of Schaaf-Yang syndrome patients.
insulin	disease_to_mechanism	leptin	1	6.936	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_mechanism	insulin	1	6.936	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_mechanism	alanine aminotransferase	1	6.936	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
insulin	disease_to_mechanism	hemoglobin a1c	1	6.936	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
autism	disease_to_mechanism	saβ precursor proteinα	1	8.77	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
alzheimer disease	disease_to_mechanism	saβ precursor proteinα	1	8.77	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
fragile x syndrome	disease_to_mechanism	saβ precursor proteinα	1	8.77	21482951	PMID:21482951; Original text:The relatively lower sAβ precursor proteinα level in Alzheimer disease may contribute to Alzheimer disease symptoms that significantly contrast with those of fragile X syndrome and autism.
